NAT2 and tuberculosis: Such a multicentric geographically diverse exploration of the NAT2 SNP is imperative for deriving a strong conclusive statement for the potential use of NAT2 genotyping as a preemptive biomarker for AT-DILI monitoring for national-level policy implementation, consideration of geographic-specific NAT2 SNPs for AT-DILI monitoring, as well as futuristic exploration of using NAT2 genotype as a potential covariate for isoniazid dose optimization in TB patients.